4-Fluoromethylphenidate (4F-MPH)
4F-MPH is a fluorinated analogue of methylphenidate (Ritalin) sold as a research chemical, reported to be more potent and longer-lasting than the parent drug. It is a norepinephrine-dopamine reuptake inhibitor with high abuse potential and essentially no human safety data.
01 Overview
4-Fluoromethylphenidate adds a fluorine to the phenyl ring of methylphenidate, increasing binding affinity at the dopamine transporter in vitro. It appeared as a grey-market stimulant in the mid-2010s among users seeking a stronger methylphenidate-like experience.
No clinical studies exist. Its increased potency, combined with insufflation and compulsive redosing reported anecdotally, raises concern for vasoconstriction, cardiovascular events and dependence.
02 Mechanism
Potent norepinephrine-dopamine reuptake inhibitor at the phenidate pharmacophore; the 4-fluoro substitution increases dopamine transporter affinity.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light (approximate, anecdotal) | 3–10 mg | Insufflated | Associated with vasoconstriction; strongly discouraged. |
| Common (approximate, anecdotal) | 5–15 mg | Oral | More potent than methylphenidate; user-reported only. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Focus and stimulationMarked wakefulness and concentration, reportedly stronger than methylphenidate. | Strong | Anecdotal | |
| Compulsive redosingUsers describe urge to redose, typical of potent phenidates. | Moderate-strong | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Peripheral vasoconstrictionCold extremities and vasoconstriction reported, a known phenidate effect. | Moderate | Common | Anecdotal | |
| Insomnia and anxietyLong duration causes marked sleep loss and jitteriness. | Moderate | Common | Anecdotal |